MBS-002

MBS-002 is an early discovery-stage **small molecule agonist** program from **MBS** directed against an **undisclosed target affecting T regulatory cell biology**. Based on the company pipeline description, the program is intended to modulate **Treg biology** through agonism of a confidential target, but no specific molecular target, disease indication, route of administration, formulation, or clinical data have been publicly disclosed. The asset appears to remain in **preclinical discovery / early lead generation**.

Other names

MBS-002-MBS-undisclosed target affecting T regulatory cell biology-small molecule agonistMBS002-MBS-undisclosed target affecting T regulatory cell biology-small molecule agonistMBS 002-MBS-undisclosed target affecting T regulatory cell biology-small molecule agonist